St. Jude Children's Research Hospital, Memphis, TN.

Search for other works by this author on: ...

The investigational HER2-selective tyrosine kinase inhibitor zongertinib appears remarkably effective in patients with HER2-mutant non–small cell lung cancer. Robust, durable responses were seen in ...

According to data announced today at the American Association for Cancer Research Annual Meeting 2025, Merck’s anti-PD-1 mAb pembrolizumab (Keytruda) led to significant improvements in event-free ...

1Department of Pathology, Stanford University School of Medicine, Stanford, California.

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Priti Bandi, Risk Factors and Screening Research, Surveillance and Health Equity Science, ...

Search for other works by this author on: ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Search for other works by this author on: ...

Renowned scientist Douglas Hanahan, PhD, discusses the legacy of The Hallmarks of Cancer, the challenge of adaptive resistance, and how insights into the tumor microenvironment and cancer neuroscience ...

Search for other works by this author on: ...

Daniel Drucker, a pioneer in GLP-1 receptor–agonist research, discusses the history of the drugs, their wide-ranging benefits, and how they might benefit patients with cancer. On April 28, 2005, the ...